Loading stock data…
Compugen Ltd. (CGEN)
$2.16+0.07 (+3.35%)
Market ClosedLast close Jun 29
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Compugen Ltd. in the Healthcare sector is trading at $2.16 with a market capitalization of $207M. Wall Street consensus targets $4.60 (5 analysts), implying a +113.0% move over the next 12 months. The stock is currently 33% below its 52-week high of $3.24, remaining 8.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +113.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.18M↓ | $67.33M↑ | $1.89M↑ | $1.26M↓ | $2.28M |
| Gross Profit | $352,000↓ | $63.80M↑ | $241,000↑ | -$408,000↓ | -$116,000 |
| Operating Income | -$9.02M↓ | $56.04M↑ | -$7.89M↑ | -$8.43M↓ | -$8.39M |
| Net Income | -$7.67M↓ | $56.84M↑ | -$6.98M↑ | -$7.34M↓ | -$7.18M |
Peer Comparison
JNJUNHPFE
Fundamentals
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consist...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$207.14M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.76
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.55%
Volume
Today's trading volume
255,204
Recent News
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions
Compugen’s analyst story has shifted, with one research firm cutting its price target from US$13 to US$5 while another framework holds a fair value estimate at US$4.6. That split echoes the latest commentary, where bullish analysts keep positive ratings but more cautious voices point to tighter assumptions and a reduced upside case. As you read on, you will see how to track these changing signals and what they might mean for following the evolving Compugen narrative over time. Stay updated as...
Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views
The recent cut in Compugen’s price target from US$13 to US$5, alongside a fair value reset from US$6.25 to US$4.60, marks a clear shift in how the stock is being valued. Some analysts still see room between the current share price and the revised US$5 target, while others are using the lower levels to reflect tighter assumptions and higher perceived risk. As you read on, you will see what is driving this split view and how to track the evolving story around Compugen. Wall Street's queuing for...
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Compugen Ltd (CGEN) showcases promising clinical progress and a strong cash position, despite facing revenue and net loss hurdles in Q1 2026.
Compugen Q1 Earnings Call Highlights
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?